Vivos Therapeutics, Inc.
VVOS
$2.63
-$0.08-2.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 18.02% | 18.46% | 35.78% | 22.62% | 43.04% |
| Total Depreciation and Amortization | -6.44% | -8.58% | -11.83% | -26.28% | -7.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 143.51% | 194.33% | -169.29% | 922.06% | -198.40% |
| Change in Net Operating Assets | -202.65% | -144.61% | -58.89% | 49.13% | 67.39% |
| Cash from Operations | -6.24% | -2.47% | 27.09% | 35.91% | 39.01% |
| Capital Expenditure | 33.41% | 36.04% | 36.45% | 34.58% | 7.68% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 33.41% | 36.04% | 36.45% | 34.58% | 7.68% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 60.31% | 146.71% | 93.01% | -0.74% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -26.37% | -108.84% | -29.92% | -14.42% | -- |
| Cash from Financing | 63.65% | 150.03% | 98.55% | -2.07% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 346.11% | 192.88% | 133.96% | 58.87% | 90.85% |